Treatment of advanced pseudomyxoma peritonei using cytoreductive surgery including total gastrectomy and perioperative chemotherapy

2021 ◽  
Author(s):  
Paul H. Sugarbaker ◽  
David Chang
Keyword(s):  
Total Gastrectomy ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Perioperative Chemotherapy

Tailgut Cyst, an Unusual Cause of Pseudomyxoma Peritonei

2009 ◽  
Vol 95 (4) ◽  
pp. 514-517 ◽  
Author(s):  
Luis Zappa ◽  
Thomas A Godwin ◽  
Paul H Sugarbaker
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Clinical Information ◽  
Malignant Degeneration ◽  
Tailgut Cyst ◽  
Perioperative Chemotherapy ◽  
Retrorectal Space ◽  
One Year ◽  
Tumor Spillage ◽  
Free Status

Background Retrorectal hamartoma, also known as tailgut cyst, is a rare tumor that arises from remnants of the embryonic postanal gut. The tumor occurs in the retrorectal space and may undergo malignant degeneration. Methods The clinical information on a single patient with pseudomyxoma peritonei associated with a tailgut cyst was reviewed and a literature review of the subject performed. Results In this patient there was malignant degeneration of a tailgut cyst localized to the pelvis. Twenty months later a local recurrence in the pelvis and pseudomyxoma peritonei widely distributed in the abdomen were successfully treated by cytoreductive surgery and perioperative chemotherapy. Conclusion Tailgut cyst may, if resected with tumor spillage, result in pseudomyxoma peritonei. Our treatment – which has maintained a disease-free status for one year – was cytoreductive surgery plus perioperative chemotherapy.

Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei

2009 ◽  
Vol 99 (5) ◽  
pp. 292-295 ◽  
Author(s):  
Terence C. Chua ◽  
Tristan D. Yan ◽  
Zhu L. Yap ◽  
Matthew D. Horton ◽  
Gary G. Fermanis ◽  
...  
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei

scholarly journals Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei

2021 ◽  
Vol 38 (2) ◽  
pp. 253-253
Author(s):  
Olaf Sørensen ◽  
Anders Mikal Andersen ◽  
Stein Gunnar Larsen ◽  
Karl‑Erik Giercksky ◽  
Kjersti Flatmark
Keyword(s):  
Experimental Model ◽  
Mitomycin C ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei

Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery

2020 ◽  
Vol 30 (8) ◽  
pp. 4193-4200
Author(s):  
Masatoshi Hotta ◽  
Ryogo Minamimoto ◽  
Yoshimasa Gohda ◽  
Tsuyoshi Tajima ◽  
Tomomichi Kiyomatsu ◽  
...  
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei

scholarly journals Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei

2019 ◽  
Vol 36 (6) ◽  
pp. 511-518 ◽  
Author(s):  
Olaf Sørensen ◽  
Anders Mikal Andersen ◽  
Stein Gunnar Larsen ◽  
Karl-Erik Giercksky ◽  
Kjersti Flatmark
Keyword(s):  
Mitomycin C ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Male Rats ◽  
High Grade ◽  
Regional Hyperthermia ◽  
Tumor Spread ◽  
Modest Improvement ◽  
Normothermic Group

Abstract Pseudomyxoma peritonei (PMP) is a rare cancer commonly originating from appendiceal neoplasms that presents with mucinous tumor spread in the peritoneal cavity. Patients with PMP are treated with curative intent by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The value of adding HIPEC to CRS has not been proven in randomized trials, and the objective of this study was to investigate the efficacy of intraperitoneal mitomycin C (MMC) and regional hyperthermia as components of this complex treatment. Xenograft tissue established from a patient with histologically high-grade PMP with signet ring cell differentiation was implanted intraperitoneally in 65 athymic nude male rats and the animals were stratified into three treatment groups; the cytoreductive surgery group (CRSG, CRS only), the normothermic group (NG, CRS and intraperitoneal chemotherapy perfusion (IPEC) with MMC at 35 ºC), and the hyperthermic group (HG, CRS and IPEC at 41 ºC). The main endpoints were survival and tumor weight at autopsy. Adequate imitation of the clinical setting and treatment approach was achieved. The median survival was 31 days in the CRSG, 60 days in NG and 67 days in HG. The median tumor weights at autopsy were 34 g in CRSG, 23 g NG and 20 g in HG. In conclusion, the addition of IPEC with MMC after CRS doubled the survival time and reduced tumor growth compared to CRS alone. Adding regional hyperthermia resulted in a modest improvement of treatment outcome.

Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei

2019 ◽  
Vol 26 (5) ◽  
pp. 1429-1436 ◽  
Author(s):  
Joal D. Beane ◽  
Gregory C. Wilson ◽  
Jeffrey M. Sutton ◽  
Yongli Shuai ◽  
Lekshmi Ramalingam ◽  
...  
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Intraperitoneal Chemoperfusion
Sign in / Sign up

Export Citation Format

Share Document